6RLN

Crystal structure of RIP1 kinase in complex with GSK3145095


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.87 Å
  • R-Value Free: 0.232 
  • R-Value Work: 0.194 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.

Harris, P.A.Marinis, J.M.Lich, J.D.Berger, S.B.Chirala, A.Cox, J.A.Eidam, P.M.Finger, J.N.Gough, P.J.Jeong, J.U.Kang, J.Kasparcova, V.Leister, L.K.Mahajan, M.K.Miller, G.Nagilla, R.Ouellette, M.T.Reilly, M.A.Rendina, A.R.Rivera, E.J.Sun, H.H.Thorpe, J.H.Totoritis, R.D.Wang, W.Wu, D.Zhang, D.Bertin, J.Marquis, R.W.

(2019) Acs Med.Chem.Lett. 10: 857-862

  • DOI: 10.1021/acsmedchemlett.9b00108

  • PubMed Abstract: 
  • RIP1 regulates cell death and inflammation and is believed to play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases and cancer. While small-molecule inhibitors of RIP1 kinase have be ...

    RIP1 regulates cell death and inflammation and is believed to play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases and cancer. While small-molecule inhibitors of RIP1 kinase have been advanced to the clinic for inflammatory diseases and CNS indications, RIP1 inhibitors for oncology indications have yet to be described. Herein we report on the discovery and profile of GSK3145095 (compound 6 ). Compound 6 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses. Highlighting its potential as a novel cancer therapy, the inhibitor was also able to promote a tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures. Compound 6 is currently in phase 1 clinical studies for pancreatic adenocarcinoma and other selected solid tumors.


    Organizational Affiliation

    S. Arthur Localio Laboratory and Department of Cell Biology, New York University School of Medicine, 550 First Avenue, New York, New York 10016, United States.,Pattern Recognition Receptor DPU and Medicinal Science & Technology, GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States.,Medicinal Science & Technology, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Receptor-interacting serine/threonine-protein kinase 1
A, B
303Homo sapiensMutation(s): 4 
Gene Names: RIPK1 (RIP, RIP1)
EC: 2.7.11.1
Find proteins for Q13546 (Homo sapiens)
Go to Gene View: RIPK1
Go to UniProtKB:  Q13546
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
K8K
Query on K8K

Download SDF File 
Download CCD File 
A, B
~{N}-[(3~{S})-7,9-bis(fluoranyl)-2-oxidanylidene-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-3-(phenylmethyl)-1~{H}-1,2,4-triazole-5-carboxamide
C20 H17 F2 N5 O2
ATQAGKAMBISZQM-HNNXBMFYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.87 Å
  • R-Value Free: 0.232 
  • R-Value Work: 0.194 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 101.840α = 90.00
b = 130.790β = 90.00
c = 48.830γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
Aimlessdata scaling
XDSdata reduction
BUSTERrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2019-07-03
    Type: Initial release